ApoVax, Inc.


ApoVax, Inc. is based on the work of Haval Shirwan, Ph.D. at the University of Louisville.
ApoVax104, an immunostimulatory adjuvant construct, consists of streptavidin fused to the costimulatory molecule 4-1BBL. It is well differentiated from other adjuvants. ApoVax104 can be mixed with or conjugated to any biotinylated antigen (or peptide)--cancer or infectious disease.
ApoVax is also developing ApoFasL—a means of immunomodulation for tolerance induction—for the treatment of Type 1 diabetes.
Rankings by

National Ranking14171st
in United States Regional Ranking15350th
in North America Global Ranking32097th
worldwide